Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

LWNVIVAT

Financiado

Limiting West Nile Virus impact by novel vaccines and therapeutics approaches

West Nile virus (WNV) is considered one of the most widespread mosquito-borne viral disease in the world. While most of WNV infected individuals are asymptomatic, 1% of WNV-infected individuals develop a severe illness that affect... ver más

30/11/2027

FUNDACIO PRIVADA I...

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

FUNDACIO PRIVADA INSTITUT DE RECERCA DE LA SI... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 5M€

Ver 8 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-11-23

HORIZON-HLTH-2023-DISEASE-03-18: Pandemic preparedness and response:... ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or...

I+D

Cerrada hace 1 año

0% 100%

8 Participantes

FUNDACIO PRIVADA INSTITUT DE...

2.13M€ | Lider

INSERM

97.29K€ | Participante

UNIVERSITE DE MONTPELLIER

1.22M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

FLAVIVACCINE Development and characterization of a pan-flavivirus vaccine... 8M€ Cerrado

MARVAX Development of novel viral vectored vaccines against Marburg... 7M€ Cerrado

Yellow4FLAVI Deconstructing the protective immunity of yellow fever virus... 8M€ Cerrado

BIO2014-52683-R DISEÑO Y EVALUACION DE INMUNOGLOBULINAS COMO MOLECULAS TERAP... 278K€ Cerrado

FLAVIR Universal building blocks for antigen presentation to uncove... 2M€ Cerrado

BES-2009-015971 BIOLOGIA DEL VIRUS VACCINIA Y SU APLICACION COMO VACUNA CONT... 11K€ Cerrado

Duración del proyecto: 48 meses Fecha Inicio: 2023-11-23
Fecha Fin: 2027-11-30

Líder del proyecto

FUNDACIO PRIVADA INSTITUT DE RECERCA DE LA SI... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 5M€

Presupuesto del proyecto 6M€

Descripción del proyecto West Nile virus (WNV) is considered one of the most widespread mosquito-borne viral disease in the world. While most of WNV infected individuals are asymptomatic, 1% of WNV-infected individuals develop a severe illness that affects the central nervous system, causing encephalitis or meningitis and eventually the death. The case-fatality rate notoriously increases in immunosuppressed individuals and in population over 60 years old (up to 30%) and, to date, there is no prophylaxis or treatment for this disease. Here, we aim to develop a safety prophylactic WNV vaccine that cover WNV diversity and protect elderly individuals by promoting the generation of potent and long-lasting neutralizing humoral and T cell responses, with limited or no cross-reactive activity against other flaviviruses. If success, the present proposal may guide the development of effective vaccines against other viruses, particularly flaviviruses. Methods: We will use outstanding computational tools to design novel Envelope-based immunogens that cover the global WNV genetic variability. Immunogens will be designed for eliciting highly-specific neutralizing humoral responses, with limited potential to mediate antibody-dependent enhancement (ADE) of infection or disease. In addition, we will also seek for T cell responses that work synergistically with antibodies to generate a long-lasting and polyfunctional protective anti-WNV immune response. Besides a classical and highly effective recombinant protein-based vaccine approach, we will explore novel and innovative strategies based on Virus Like Particles, and the use of antibodies as adjuvants, that may improve vaccine immunogenicity and efficacy. For immunogenicity analysis we have designed a complete set of assays that encompasses from in vitro testing, using human immune cells (tonsil and PBMCs) to in vivo evaluation using both young and old mice, and a complementary swine model.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores